Announcing Prime's new quarterly publication, the GLP-1 Pipeline Update! Prime is committed to helping our customers stay ahead of the curve when it comes to GLP-1s. In our GLP-1 Pipeline Update, we track the earliest estimated approvals for GLP-1s new indications. Take a look to learn all about what drugs and changes are coming soon, potentially even as early as December 2024: https://bit.ly/4i14NNJ
Prime Therapeutics
保险业
Eagan，MN 60,916 位关注者
Reimagining pharmacy management to provide the same care we would want for our loved ones
关于我们
We’re reimagining pharmacy solutions to provide the care we would want for our loved ones. Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. We offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, we’re reimagining pharmacy solutions to provide the care we’d want for our loved ones. We challenge the way it’s always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health.
- 网站
-
www.primetherapeutics.com
Prime Therapeutics的外部链接
- 所属行业
- 保险业
- 规模
- 1,001-5,000 人
- 总部
- Eagan，MN
- 类型
- 私人持股
- 创立
- 1998
- 领域
- Pharmacy Benefits Management
地点
Prime Therapeutics员工
动态
-
Have you read about the latest trends in medical pharmacy? Vaccine utilization across the commercial space rose 169.6% in 2023, led in part by the approval of three new vaccines for respiratory syncytial virus (RSV), as well as full FDA approval for yearly COVID vaccine doses. Across all lines of business, spend on 505(b)(2) agents increased by double digits; however, overall trend for drugs in this space decreased because of lower spend for the innovator products. Read the 2024 Medical Pharmacy Trend Report for more data and expert insights here: https://bit.ly/3OfR8oD
-
-
Hear from Simone Ndujiuba, PharmD, BCOP as she discusses the difference between oncology case management and navigation in the latest Oncology Insights. Learn more: https://bit.ly/4hXMs4q
-
Catch up on the last deep dives of the year! This edition explores therapies for rare diseases like congenital adrenal hyperplasia and familial chylomicronemia syndrome. Highlighted new treatments include: ?? Moderate to severe acute pain ?? Non-small lung cancer ?? Obstructive sleep apnea with obesity Read our latest pipeline to stay ahead of evolving indications and treatments here: https://bit.ly/3OaxtXa
-
Can you tell if a glucagon-like peptide-1 (GLP-1) drug is fake? Jessica Johnson, clinical consultant at Prime’s Special Investigations Unit, shares how to identify and avoid counterfeit GLP-1s. Read more: https://bit.ly/3Zck07y
-
-
Maryam Tabatabai and Prime’s government affairs experts Caitlin Berry and Julie Cantor-Weinberg sat down for a timely discussion about the election. Listen in for insights on how the election may impact health care and pharmacy benefit management here: https://bit.ly/4ffsuQk
-
-
At Prime, we’re focused on putting more care in health care. That starts with the people who work on our front lines. Watch recruiter Tracy Meichsner share why Prime is a great place to work if you want to make a difference: https://bit.ly/4eDfjYS
-
International Fraud Awareness Week recognizes efforts to minimize the impacts of fraud on businesses. This week — and every week — Prime is working to fight health care fraud. Our dedicated fraud, waste and abuse team brings their expertise to drive cost savings, promote cost avoidance and increase member safety.
-
-
Take a closer look at our snapshot of new drugs expected to hit the market in November here: https://bit.ly/4hcR5XX
-
Our newest High-Cost Therapy Profile has arrived. Dive deeper with our experts: https://bit.ly/40haKzE